Hello, we are GCCL, a leading global clinical all-in-one lab in APAC. 👋
In 2025, one of the hottest keywords in the pharmaceutical & biotech industry is likely obesity therapeutics.
In this article, we’ll cover development trends and bioanalysis strategies for obesity & metabolic therapeutics.
Where the obesity drug market is headed,
and why clinical sample analysis is a core driver of decision-making in drug development.
🎯 Obesity Therapeutics Market: Growth Drivers & Demand Structure
The World Health Organization (WHO) defines BMI ≥ 25 as overweight and BMI ≥ 30 as obesity.
If the obesity prevalence trends observed over the past 30 years continue, by 2050 more than half of the global population aged 25+ (approximately 3.8 billion people) is projected to be overweight or obese.
– GBD (Global Burden of Disease) research team
Accordingly, the obesity therapeutics market is expected to grow rapidly not only in Korea but worldwide. JP Morgan Research projected the market to reach approximately USD 100 billion by 2030, and GlobalData projected approximately USD 173.5 billion by 2031.
Obesity increases the risk of multiple comorbidities including type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia, MASH, and cancer, driving higher overall mortality and increasing healthcare costs.
Against this backdrop, the obesity therapeutics market has been evolving at an unprecedented pace. With the emergence of GLP-1 class drugs, obesity is increasingly recognized not merely as a lifestyle issue but as a treatable disease. As a result, global pharma and biotech companies are actively prioritizing obesity therapeutics as a next-generation core pipeline area. In particular, as patent expiries for major GLP-1 drugs (including semaglutide) are expected between 2026 and 2032, competition among global pharma and biotechs is accelerating. In parallel, diverse approaches including dual/triple agonists, long-acting formulations, and oral formulations—are being explored, making development trends increasingly complex.
📊 Development Trend 1: GLP-1–Based Therapies & Multi-Target Competition
The obesity therapeutics market has achieved remarkable growth with the emergence of glucagon-like peptide-1 (GLP-1) class drugs. Today, Novo Nordisk and Eli Lilly are leading the market.
The brain, particularly the hypothalamus is central to appetite and weight regulation. The arcuate nucleus (ARC) senses circulating nutrients and hormones and controls intake through the balance between appetite-suppressing POMC neurons and appetite-stimulating NPY/AgRP neurons. In addition, the nucleus tractus solitarius (NTS) in the brainstem receives gastrointestinal satiety signals and interacts with the hypothalamus to form an appetite-regulation network.
Food intake also affects the reward system beyond homeostatic control. The mesolimbic dopamine pathway, activated when consuming palatable foods, contributes to hedonic feeding; in obesity, excessive activation of this circuit may drive weight gain.
Based on this gut–brain axis understanding, incretin-based drugs have emerged as a key strategy. GLP-1 is known to be secreted from intestinal L cells after meals, stimulate insulin secretion, suppress appetite, and delay gastric emptying. GLP-1 receptors are expressed not only in the hypothalamus and brainstem but also in reward circuits, enabling regulation of both food intake and weight loss.
Next-generation obesity therapeutics are expanding beyond GLP-1 monotherapy toward multi-receptor (dual/triple) targeting. With renewed interest in the role of GIP, dual agonists targeting both GLP-1 and GIP have emerged as a promising alternative.
For example, tirzepatide has been approved with up to ~20% weight loss reported in clinical studies. Novo Nordisk is evaluating the semaglutide + amylin analog (cagrilintide) combination (CagriSema) in Phase 3. Amgen is also developing a candidate (MariTide) using a GLP-1 agonist / GIP antagonist strategy.
Key Point
As development shifts from GLP-1 monotherapy → dual/triple approaches such as GLP-1/GIP and GLP-1/GIP/Glucagon, drug structures and formulation designs become more complex, increasing the importance of precise bioanalysis strategies.
📊 Development Trend 2: Formulation Diversification (Convenience & Durability)
Following the success of GLP-1 class obesity drugs, competition is expanding beyond “mechanism of action” to how convenient the dosing is, how long it lasts, and how easily it can be administered. Because obesity treatment often requires long-term therapy, patient adherence and persistence can directly impact clinical outcomes.
1) Predominantly SC injections → Long-acting formulations
Most commercially available GLP-1 obesity drugs are subcutaneous (SC) injections. Weekly dosing options such as semaglutide and tirzepatide have significantly reduced treatment burden. However, as chronic treatment perspectives strengthen, long-acting formulations targeting monthly dosing or longer (e.g., depot, microsphere/hydrogel, sustained-release platforms) are actively being developed.
2) The challenge of oral formulations (Oral GLP-1)
Despite the success of injectables, one of the largest unmet needs in obesity therapeutics is oral dosage forms. Because GLP-1 is peptide-based, development is challenging due to gastric acid/enzymatic degradation and low intestinal absorption. Still, increasing numbers of candidates are being explored using absorption-enhancing technologies (e.g., SNAC), peptide structural modifications, and epithelial permeability platforms, supporting ongoing discussions about a possible shift toward an oral market.
📊 Development Trend 3: Weight-Loss Rates → Clinical Value in Comorbidities
The recent direction is moving away from pure “weight-loss number competition.” As evidence accumulates that rapid weight loss may increase gastrointestinal adverse events and tolerability issues, “which endpoints improved in which diseases” is becoming more important than simply “how much weight was lost.”
Many patients with obesity have one or more comorbidities such as type 2 diabetes, hypertension, cardiovascular disease (CV), chronic kidney disease (CKD), sleep apnea, and MASH. In comorbidity areas, clear clinical endpoints exist, economic impact is easier to explain, and value-based contracting potential is higher, linking directly to market access and payer strategies.
📘 Summary of the Strategic Shift
- GLP-1 mono agonists → expansion to GLP-1/GIP, GLP-1/GCG, triple agonists, etc.
- Injectable → diversification into oral and long-acting formulations
- Weight-loss → disease-specific clinical value (comorbidity data)–driven designs
In this trend, the role of bioanalysis data becomes even more critical.
📊 Why is Bioanalysis for Obesity Therapeutics Challenging?
Recent obesity therapeutics vary widely by drug structure (peptide/modified), dosing approach (long-acting/oral), and dosing duration (long-term), which can lead to differences in PK profiles, immunogenicity (ADA) patterns, and biomarker response dynamics. In particular, high-dose and long-term dosing characteristics often introduce unique analytical complexities compared with typical small molecules or protein therapeutics.
Therefore, obesity drug development increasingly requires PK study designs aligned with formulation characteristics, ADA strategies that reflect long-term dosing, and biomarker panel analyses that extend beyond weight loss to include metabolic, fibrosis, and inflammation indicators.
1) Complexity of Peptide PK Analysis
GLP-1 class drugs are peptide-based and often incorporate structural modifications such as fatty-acid conjugation. LC-MS/MS–based PK analysis may involve multiple challenges including quantitation, structural confirmation, and matrix effects.
2) Challenges in Immunogenicity (ADA) Assessment
Given the long-term dosing nature of these therapeutics, ADA and neutralizing antibody (NAb) assessments are key components of clinical development.
3) Complexity in Biomarker Analysis
As studies increasingly track not only weight loss but also metabolic, inflammatory, and fibrotic endpoints, biomarker panel selection, interpretation, and long-term follow-up designs become more important.
📊 GCCL’s Approach: One-Stop Integrated PK · ADA · Biomarker Bioanalysis
For obesity therapeutics, it is increasingly important to design and operate PK, ADA, and biomarker programs not in isolation but in an integrated manner aligned with clinical decision-making. Based on experience in peptide therapeutics and capabilities in LC-MS/MS and LBA method development, GCCL provides a one-stop integrated bioanalysis platform covering PK + ADA + Biomarkers.
> Blog